News
IVA
5.07
-2.69%
-0.14
Inventiva announces shareholder meeting notice
PUBT · 2d ago
Inventiva CEO presents at Jefferies Global Healthcare Conference
PUBT · 3d ago
Inventiva says JPMorgan Chase holds 5.62% beneficial stake
PUBT · 3d ago
Inventiva reports JPMorgan beneficial stake at 5.25% of capital, 5.03% voting rights
PUBT · 6d ago
Weekly Report: what happened at IVA last week (0511-0515)?
Weekly Report · 6d ago
Inventiva's Speculative Upside Through MASH Is Promising
Seeking Alpha · 05/15 22:22
Inventiva presents lanifibranor MASH data at EASL Congress 2026
PUBT · 05/13 09:16
Inventiva to present lanifibranor MASH trial data at EASL Congress 2026
PUBT · 05/13 06:30
Weekly Report: what happened at IVA last week (0504-0508)?
Weekly Report · 05/11 09:56
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 5/8/2026
TipRanks · 05/08 22:44
Weekly Report: what happened at IVA last week (0427-0501)?
Weekly Report · 05/04 09:55
Weekly Report: what happened at IVA last week (0420-0424)?
Weekly Report · 04/27 09:57
Inventiva Bolsters C-Suite Ahead of Lanifibranor Phase 3 Readout
TipRanks · 04/22 21:00
Inventiva announces CFO appointment
Seeking Alpha · 04/22 20:21
Inventiva CFO Jean Volatier to switch roles, Axel-Sven Malkomes to succeed
TipRanks · 04/22 20:16
Inventiva Recruits Axel-Sven Malkomes As New CFO
Benzinga · 04/22 20:02
Inventiva names Axel-Sven Malkomes CFO in leadership reshuffle
PUBT · 04/22 20:00
INVENTIVA STRENGTHENS LEADERSHIP TEAM AHEAD OF EXPECTED PHASE 3 DATA READOUT OF LANIFIBRANOR
Reuters · 04/22 20:00
Weekly Report: what happened at IVA last week (0413-0417)?
Weekly Report · 04/20 09:54
More
Webull provides a variety of real-time IVA stock news. You can receive the latest news about Inventiva S.A. through multiple platforms. This information may help you make smarter investment decisions.
About IVA
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.